

BAXTER INTERNATIONAL INC.
Reconciliation of GAAP to Non-GAAP Net Sales Measures
Periods Ending June 30, 2010 and 2009
(unaudited)
(\$ in millions)

The company's GAAP net sales results for the six months ended June 30, 2010 included a \$213 million charge related to the recall of COLLEAGUE infusion pumps from the U.S. market, which impacted GAAP net sales as follows:

	2010 YTD			2009 YTD			% Growth @ Actual Rates			% Growth @ Constant Rates		
	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total	U.S.	International	Total
Infusion Systems - GAAP			\$212			\$404			(48%)			(52%)
COLLEAGUE infusion pump charge			213									
Infusion Systems - Adjusted			\$425			\$404			5%			1%
Total Medication Delivery - GAAP	\$978	\$1,230	\$2,208	\$1,060	\$1,109	\$2,169	(8%)	11%	2%	(8%)	1%	(3%)
COLLEAGUE infusion pump charge	213		213									
Total Medication Delivery - Adjusted	\$1,191	\$1,230	\$2,421	\$1,060	\$1,109	\$2,169	12%	11%	12%	12%	1%	7%
Total Baxter - GAAP	\$2,435	\$3,686	\$6,121	\$2,566	\$3,381	\$5,947	(5%)	9%	3%	(5%)	1%	(1%)
COLLEAGUE infusion pump charge	213		213									
Total Baxter - Adjusted	\$2,648	\$3,686	\$6,334	\$2,566	\$3,381	\$5,947	3%	9%	7%	3%	1%	2%

For more information on the company's use of non-GAAP financial measures in this press release, please see the company's Current Report on Form 8-K filed with the Securities and Exchange Commission on the date of this press release.